A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

SCLC Clinical Trial

Official title:

A Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of PM8002 in Combination With Etoposide and Platinum in First-line Treatment of Extensive-Stage Small Cell Lung Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05844150
• Other study ID #: PM8002-BC011C-SCLC-R
• Status: Recruiting
• Phase: Phase 2/Phase 3
• Start date: June 1, 2023
• Est. completion date: December 2025

Study information

• Verified date: May 2023
• Source: Biotheus Inc.
• Contact: Zhishuo Cheng
• Phone: +86 021 32120207
• Email: cheng.zs[@]biotheus.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study to evaluate the efficacy and safety of PM8002 in combination with etoposide and platinum in first-line treatment of extensive-stage small cell lung cancer

Description:

The study is divided into two parts.

The first part is single-arm study, with a planned enrollment of at least 59 subjects.

The second part is randomized, double-blind study, this study plans to enroll 386 subjects, who will be randomized in a 1:1 ratio to an experimental group of PM8002 in combination with chemotherapy (etoposide and platinum) and a control group of Atezolizumab with chemotherapy (etoposide and platinum).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 445
• Est. completion date: December 2025
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Signed informed consent form before any trial-related processes;

2. Age =18 years;

3. Histologically or cytologically confirmed ES-SCLC;

4. No prior systemic therapy for ES-SCLC;

5. Have adequate organ function;

6. The Eastern Cancer Cooperative Group (ECOG) performance score of 0 or 1;

7. Life expectancy of =12 weeks;

8. Had at least one measurable tumor lesion according to RECIST v1.1.

Exclusion Criteria:

1. Histologically or cytologically confirmed mixed SCLC;

2. History of severe allergic disease, severe drug allergy or have known allergy to any component of the study drugs;

3. The toxicity of previous anti-tumor therapy has not been alleviated;

4. Have received anti-platelet therapy within 10 days prior to the first dose of the study drugs;

5. Evidence and history of severe bleeding tendency;

6. History of severe cardiovascular diseases within 6 months;

7. Current presence of uncontrolled pleural, pericardial, and peritoneal effusions;

8. History of allogeneic hematopoietic stem cell transplantation or allogeneic organ transplantation;

9. History of alcohol abuse, psychotropic substance abuse or drug abuse;

10. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome;

11. Pregnant or lactating women;

12. Other conditions considered unsuitable for this study by the investigator.

Related Conditions & MeSH terms

• SCLC

Intervention

Drug:
• PM8002
IV infusion
• Platinum
IV infusion
• Atezolizumab
IV infusion
• Etoposide
IV infusion

Locations

Country	Name	City	State
China	Jilin Cancer Hospital	Changchun

Sponsors (1)

Lead Sponsor	Collaborator
Biotheus Inc.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective response rate (Part 1)	Objective response rate (ORR) is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1.	Up to approximately 2 years
Primary	Overall survival (Part 2)	Overall survival (OS) is the time from the date of randomization or first dosing date to death due to any cause.	Up to approximately 2 years
Secondary	Overall survival (Only for Part 1)	OS is the time from the date of randomization or first dosing date to death due to any cause.	Up to approximately 2 years
Secondary	Progression free survival (PFS)	Progression free survival (PFS) is defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first (based on RECIST v1.1).	Up to approximately 2 years
Secondary	Disease control rate (DCR)	DCR is defined as the proportion of subjects with CR, PR, or stable disease (SD) based on RECIST v1.1.	Up to approximately 2 years
Secondary	Duration of response (DOR)	DOR is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST v1.1) or death due to any cause, whichever occurs first.	Up to approximately 2 years
Secondary	Time to response (TTR)	TTR is defined as the time from the start of the treatment to the first objective tumor response observed for patients who achieve CR or PR (based on RECIST v1.1).	Up to approximately 2 years
Secondary	Objective response rate (ORR) (Only for Part 2)	Objective response rate (ORR) is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1.	Up to approximately 2 years
Secondary	Pharmacokinetic (PK) parameters	The PK parameters including serum concentrations of PM8002 at different time points after study drug administration.	Up to 30 days after last treatment
Secondary	Anti-drug antibody (ADA)	To evaluate the incidence of ADA to PM8002.	Up to 30 days after last treatment
Secondary	Treatment related adverse events (TRAEs)	The incidence and severity of TRAEs graded according to NCI-CTCAE v5.0	Up to 30 days after last treatment